Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

ase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned, including any further clinical trials of any of the Company's product candidates; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended June 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking sta
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015  Adaptive Biotechnologies today announced the recent ... The University of Texas MD Anderson Cancer Center ... identification and quantification of populations of B cells ... of people with classical Hodgkin,s lymphoma (CHL). The ... Haematology , represent a first step toward developing ...
(Date:4/28/2015)... ANN ARBOR, Mich. , April 28, 2015 ... OncoTargets and Therapy today shows that the Paradigm ... FoundationOne test across a number of key clinical variables, ... The purpose of the analysis was to ... for profiling cancer patients compared with each other.  ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 More than ... psychosis at some point over the course of their ... symptoms that worsen as the disease progresses. ReachMD ... announces the launch of a series dedicated to PD ... in PD, movement disorders, and psychiatric conditions. , The ...
(Date:4/28/2015)... York, New York (PRWEB) April 28, 2015 ... operations including sales, marketing, and customer service operations across ... The Eeva Test , the first and only FDA-cleared ... proprietary algorithm to aid in embryo selection during IVF. ... career in the field of Reproductive Sciences, including both ...
Breaking Biology Technology:Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 2Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 3Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2Progyny Appoints Gary Harton as Group Senior Vice President, Commercial Development 2
... Continues to ... Broaden Product Portfolio, WAYNE, Pa., Feb. 14 ... fiscal second quarter and,six months ended December 31, 2007., For ... the Company,s Drew, Vascular and Escalon Digital Solutions (EMI),business units, which ...
... PALO ALTO, Calif., Feb. 14 CV Therapeutics,Inc. ... accordance with Nasdaq,marketplace rule 4350, the Company issued ... due to additional hiring, primarily in,connection with its ... inducement stock options cover an aggregate 119,200 shares ...
... WASHINGTON, Feb. 14 As part of ... create a pathway for,FDA approval of safe and ... features a footprint in the snow stating: "Don,t ... highlights how meaningful biogenerics legislation should be,balanced to ...
Cached Biology Technology:Escalon(R) Reports Second Quarter Fiscal 2008 Results 2Escalon(R) Reports Second Quarter Fiscal 2008 Results 3Escalon(R) Reports Second Quarter Fiscal 2008 Results 4Escalon(R) Reports Second Quarter Fiscal 2008 Results 5Escalon(R) Reports Second Quarter Fiscal 2008 Results 6Escalon(R) Reports Second Quarter Fiscal 2008 Results 7Escalon(R) Reports Second Quarter Fiscal 2008 Results 8CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... , March 26, 2015 ... family, social, recreation and athletic club, today announced it ... to allow freedom of movement for members and staff, ... "Following a comprehensive process, we selected FST,s IMID Access ... and convenience for our members and staff, in addition ...
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... by a particular enzyme to modify bacterial chromosome chemistry, ... new kind of drug that could stop virulent bacterial ... in the May 6 issue of the journal Cell. ... enzyme called Dam (DNA adenine methyltransferase) plays a role ...
... that can survive encounters with specific immune system cells ... cells, known as neutrophils, dictate whether our immune system ... the research was released today online in The Journal ... Laboratories (RML), part of the National Institute of Allergy ...
... the field of human embryonic stem cell research receives ... also exploring the potential of adult stem cells for ... adult stem cell research isn't fraught with the controversies ... extremely difficult to isolate and then to multiply in ...
Cached Biology News:Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3Researchers discover mechanism for multiplying adult stem cells 2
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: